Document is current
Any future updates will be listed below
-
Authors
Motta, Irene https://orcid.org/0000-0001-5701-599X
Delbini, Paola
Scaramellini, Natalia https://orcid.org/0000-0002-5509-3107
Ghiandai, Viola https://orcid.org/0000-0002-4595-986X
Duca, Lorena https://orcid.org/0000-0002-2008-3187
Nava, Isabella
Nascimbeni, Fabio https://orcid.org/0000-0002-1051-1272
Lugari, Simonetta
Consonni, Dario https://orcid.org/0000-0002-8935-3843
Trombetta, Elena https://orcid.org/0000-0002-1933-6415
Di Stefano, Valeria https://orcid.org/0000-0003-1288-1899
Migone De Amicis, Margherita
Cassinerio, Elena https://orcid.org/0000-0003-4392-5225
Carubbi, Francesca https://orcid.org/0000-0001-7504-6407
Cappellini, Maria Domenica https://orcid.org/0000-0001-8676-6864
-
Funding
Funding for this research was provided by:
Sanofi (GZ-2014-11248, GZ-2014-11248, GZ-2014-11248, GZ-2014-11248)
Università degli Studi di Milano (PSR-DISCCO-2019)
- License Information
-
More Information
Article History
Received: 8 June 2024
Accepted: 26 July 2024
First Online: 7 October 2024
Declarations
:
: The study was approved by the ethical review committee of the center “Comitato Etico Milano Area 2” (Protocol number 1678/2016) and was carried out in compliance with the principles established in the Helsinki Declaration.
: Irene Motta has been or is a current consultant for Sanofi, Bristol Myers Squibb, and Amicus Therapeutics and has received honoraria for lectures, financial support, and grants from Sanofi.Fabio Nascimbeni has been or is a current consultant for Sanofi.Francesca Carubbi received financial support and grants from Sanofi, Amgen.Maria Domenica Cappellini has been or is a current consultant for Sanofi, Novartis, Celgene Corp (Bristol Myers Squibb), Vifor Pharma and Ionis Pharmaceuticals, and received research funding from Sanofi, Novartis, Celgene Corp (Bristol Myers Squibb), La Jolla Pharmaceutical Company, Roche, Protagonist Therapeutics, and CRISPR Therapeutics.
